The FDA reviewed labeling definitions and transcatheter valve replacement technology, noting potential benefits from Trump-era tariffs for Abbott and Edwards Lifesciences.
1 report, 1 independent
Updated Jul 9
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA reviewed labeling definitions and transcatheter valve replacement technology, noting potential benefits from Trump-era tariffs for Abbott and Edwards Lifesciences.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Abbott Laboratories
American global health care and medical device products company
-
Edwards Lifesciences
American medical technology company
Related events
Coverage
Newest first; wire copies grouped- Insider MonkeyOppenheimer Reiterates ‘Outperform’ Rating on Abbott Laboratories (ABT) Abbott Laboratories (NYSE:ABT) is one of the top 10 defensive stocks to consider in a volatile market. On July 3, analysts at O